Skip to search formSkip to main contentSkip to account menu

2-Bromoergocryptine Mesylate

Known as: Bromocriptine Mesylate, 2-Bromoergocryptine Mesylate [Chemical/Ingredient], Ergotaman-3',6',18-trione, 2-bromo-12'-hydroxy-2'-(1-methylethyl)-5'-(2-methylpropyl)-, monomethanesulfonate (salt), (5'alpha)- 
The mesylate salt of bromocriptine, a semisynthetic ergot alkaloid with dopaminergic, antidyskinetic, and antiprolactinemic activities. Bromocriptine… 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2004
2004
There is much interest in the possibility that prolactin influences disease activity in systemic lupus erythematosus (SLE). We… 
2002
2002
BACKGROUND The complex pharmacological profile of the antiparkinsonian drug budipine influences neurotransmission beyond the… 
1994
1994
A 48-year-old man with visual disturbances and subtle features of acromegaly had elevated serum thyrotropin (thyroid-stimulating… 
1989
1989
Bromocriptine mesylate, a long-acting dopamine agonist, is a semisynthetic ergot-derived alkaloid that has been used clinically… 
1987
1987
The effects of hyperprolactinemia (hyperPRL) and hypoprolactinemia (hypoPRL) on pituitary gonadotropin secretion and the feedback… 
1986
1986
In order to examine regulation of pituitary intermediate lobe secretion, plasma immunoreactive (i)ACTH, cortisol, and alpha-MSH… 
1981
1981
IT HAS been demonstrated that treatment with bromocriptine mesylate can reduce the size of pituitary prolactinomas. 1,2 The… 
1980
1980
The efficacy and safety of bromocriptine mesylate (5 to 7.5 mg per day for up to 24 weeks) were studied in 22 clinical trials… 
1980
1980
A 64-year-old woman with active acromegaly of 33 years' duration, severe carpal tunnel syndrome, and subclinical heart disease…